This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Prewitt, R. M. Articles by Ducas, J. Search for Related Content PubMed PubMed Citation Articles by Prewitt, R. M. Articles by Ducas, J. Pubmed/NCBI databases Substance via MeSH Medline Plus Health Information Pulmonary Embolism Pulmonary Hypertension

Circulation, Vol 79, 929-938, Copyright © 1989 by American Heart Association

ARTICLES

Recombinant tissue-type plasminogen activator in canine embolic pulmonary hypertension. Effects of bolus versus short-term administration on dynamics of thrombolysis and on pulmonary vascular pressure-flow characteristics

RM Prewitt, F Shiffman, D Greenberg, R Cook and J Ducas
Department of Medicine, University of Manitoba, Winnipeg, Canada.

We used a canine model of embolic pulmonary hypertension, induced by injection of autologous radioactive blood clots, to investigate effects of recombinant tissue-type plasminogen activator (rt-PA) on dynamics of thrombolysis and on pulmonary pressure-flow (PQ) characteristics. Over 5 (rt-PA5) or 15 (rt-PA15) minutes, 1 mg/kg rt-PA was infused. Rate and extent of thrombolysis were assessed by counting over both lung fields with a gamma camera. Emboli increased mean pulmonary artery pressure from 14 to 36 mm Hg (p less than 0.005). This change was predominantly due to an increase in the effective outflow pressure (PI) (from 9 to 29 mm Hg, p less than 0.001), obtained by extrapolation from the linear PQ relation. While pulmonary hemodynamics improved with rt-PA5 and rt- PA15, the change was greatest with rt-PA15. For example, the increase in PI that occurred with embolization was abolished with rt-PA15. Also, the decrease in pulmonary artery pressure was greatest with rt-PA15. While not significantly different, extent of total clot lysis tended to be greatest with rt-PA15 (p less than 0.07). Also, while during infusion, the concentration of rt-PA5 was threefold that of rt-PA15, the corresponding rate of thrombolysis was similar with rt-PA5 and rt- PA15. These results indicate that the improvement in pulmonary hemodynamics with rt-PA is primarily explained by a decrease in PI. Furthermore, they suggest an upper limit to the dose-thrombolytic rate relation with rt-PA.

This article has been cited by other articles:

				R. B. Abu-Laban, J. M. Christenson, G. D. Innes, C. A. van Beek, K. P. Wanger, R. D. McKnight, I. A. MacPhail, J. Puskaric, R. P. Sadowski, J. Singer, et al. Tissue Plasminogen Activator in Cardiac Arrest with Pulseless Electrical Activity N. Engl. J. Med., May 16, 2002; 346(20): 1522 - 1528. [Abstract] [Full Text] [PDF]

				Shian Gu, R. M. Prewitt, U. Schick, and J. Ducas Effects of Progressive Vascular Occlusion on Slope and Intercept of the Pulmonary Artery Pressure-Flow Relationship Angiology, January 1, 1995; 46(1): 45 - 52. [Abstract] [PDF]

				R. M. Prewitt, S. Gu, U. Schick, and J. Ducas Effect of Rate of Administration of Recombinant Tissue Plasminogen Activator on Efficacy of Coronary Thrombolysis Angiology, August 1, 1994; 45(8): 687 - 694. [Abstract] [PDF]